Anti α actinin h 300

Primary antibodies used were anti-TBK1 (Alexis Biochemicals, Lausen, Switzerland), anti-TRIF (Abnova, Walnut, CA), anti–TNFR-associated factor 3 (TRAF3) (Santa Cruz Biotechnoly), and anti-β-actin (Abcam, Cambridge, U.K.), anti-IRF3 (Santa Cruz Biotechnologies), anti-Flag (Sigma-Aldrich), anti-Xpress (Invitrogen Life), Anti-α-Actinin (H-300) (Santa Cruz Biotechnologies), anti-ICP0 (Santa Cruz Biotechnologies), anti-IRF5 (Cell Signalling), anti-IRF7 (Abcam).

Cells grown in 6-well cell culture plates were fixed with 4% paraformaldehyde for 15 min, rinsed with phosphate buffer solution (PBS) three times, permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, Shanghai, China) for 15 min and then incubated in 10% normal donkey serum (Solarbio, Beijing, China)/1% BSA (Sigma-Aldrich)/0.3 M glycine (Sigma-Aldrich) for 1 h to block non-specific protein—protein interactions. The primary antibody was diluted in the blocking buffer to incubate cells overnight at 4 °C. After being washed with PBS three times, cells were incubated with secondary antibody protected from light at 37 °C for 1 h. The nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) in the dark at room temperature for 10 min. The antibodies were used as follows: anti α-actinin (H-300) (1:200, Santa Cruz Biotechnology, Shanghai, China), and donkey anti-rabbit IgG H&L (Alexa Fluor^® 555, 1:1000, abcam). DAPI was used at the final concentration of 1 μg/mL. Phase-contrast and fluorescent microscopy were performed by using an inverted fluorescence microscope (Olympus IX71, Olympus Corporation, Beijing, China).